Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance

Bristol-Myers Squibb CoTrade
Expeditors International of Wshngtn IncTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Expeditors International of Wshngtn Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while Expeditors International of Wshngtn Inc trades at $177.4 (market cap $23.04B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.6× Expeditors International of Wshngtn Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.

BMYEXPD
Market Cap
$129.94B$23.04B
Sector
HealthIndustrials
52-Week High
$65.89$182.80
52-Week Low
$42.60$113.13
Enterprise Value
$163.92B$22.57B
Dividend Yield
3.96%0.91%

Returns comparison

Trailing returns across standard periods

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Expeditors International of Wshngtn Inc

Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.

Read more on EXPD